Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Dec 31;9(12):e115869.
doi: 10.1371/journal.pone.0115869. eCollection 2014.

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts

Melanie M Hagleitner  1 , Marieke J H Coenen  2 , Ana Patino-Garcia  3 , Eveline S J M de Bont  4 , Anna Gonzalez-Neira  5 , Hanneke I Vos  1 , Frank N van Leeuwen  1 , Hans Gelderblom  6 , Peter M Hoogerbrugge  1 , Henk-Jan Guchelaar  7 , Maroeska W M Te Loo  1
Affiliations
Meta-Analysis

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts

Melanie M Hagleitner et al. PLoS One. .

Abstract

Treatment with cisplatin-containing chemotherapy regimens causes hearing loss in 40-60% of cancer patients. It has been suggested that genetic variants in the genes encoding thiopurine S-methyltransferase (TPMT) and catechol O-methyltransferase (COMT) can predict the development of cisplatin-induced ototoxicity and may explain interindividual variability in sensitivity to cisplatin-induced hearing loss. Two recently published studies however, sought to validate these findings and showed inconsistent results. The aim of this study was to evaluate the role of polymorphisms in the TPMT and COMT genes in cisplatin-induced ototoxicity. Therefore we investigated two independent cohorts of 110 Dutch and 38 Spanish patients with osteosarcoma and performed a meta-analysis including all previously published studies resulting in a total population of 664 patients with cancer. With this largest meta-analysis performed to date, we show that the influence of TPMT and COMT on the development of cisplatin-induced hearing loss may be less important than previously suggested.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Forest plots genetic variants in TPMT gene.
Figure 2
Figure 2. Forest plots genetic variants in COMT gene.
See this image and copyright information in PMC

References

    1. Knight KR, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588–8596. - PubMed
    1. Li Y, Womer RB, Silber JH (2004) Predicting cisplaitn ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 40:2445–2451. - PubMed
    1. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, et al. (2012) Risk Factors for Cisplatin-Associated Ototoxicity in Pediatric Oncology Patients. Pediatr Blood Cancer 59:144–148. - PMC - PubMed
    1. Blakley BW, Gupta AK, Myers SF, Schwan S (1994) Risk factors for ototoxicity due to cisplaitn. Arch Otolaryngol Head Neck surg 120:541–546. - PubMed
    1. Pan CC, Eisbruch A, Lee JS, Snorrason RM, Ten Haken RK, et al. (2005) Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 61:1393–1402. - PubMed

Publication types

MeSH terms